RA
KALV

Rosalind Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Rosalind Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-157,725
Closed -$1.78M – 43
2025
Q2 		$1.78M Sell
157,725
-146,139
-48% -$1.79M 0.85% 23
2025
Q1 		$3.51M Hold
303,864
– – 1.71% 21
2024
Q4 		$2.57M Hold
303,864
– – 1.32% 23
2024
Q3 		$3.52M Sell
303,864
-34,121
-10% -$429K 2.25% 16
2024
Q2 		$3.98M Buy
337,985
+50,000
+17% +$584K 3.06% 15
2024
Q1 		$3.42M Sell
287,985
-12,015
-4% -$160K 3.19% 15
2023
Q4 		$3.67M Buy
+300,000
New +$2.73M 3.03% 16

Other funds holding KALV

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rosalind Advisors's KALV Position: Q3 2025 in Review

Rosalind Advisors sold out of KalVista Pharmaceuticals (KALV) in Q3 2025, closing a stake of 157,725 shares — an estimated $1.78M sold.

Rosalind Advisors first reported a position in KALV in Q4 2023 and held it in 7 quarters. The position peaked at $3.98M in Q2 2024. 145 funds tracked by Wall St. Rank hold KALV as of Q3 2025.

  • Rosalind Advisors reported no remaining KalVista Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Rosalind Advisors sold 157,725 KalVista Pharmaceuticals shares in Q3 2025, an estimated $1.78M.
  • Rosalind Advisors first reported a position in KalVista Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Rosalind Advisors's KalVista Pharmaceuticals position peaked at $3.98M in Q2 2024.
  • 145 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2025.

Based on Rosalind Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.